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Abstract
Background: Exacerbations of non-cystic fibrosis bronchiectasis cause significant morbidity but there are few
detailed data on their clinical course and associated physiological changes. The biology of an exacerbation has
not been previously described.
The purpose of this study was to describe changes in lung function, symptoms, health status and inflammation
during the development and recovery from community-treated exacerbations.
Methods: This was a prospective observational cohort study of 32 outpatients with non-cystic fibrosis bronchiectasis
conducted between August 2010 and August 2012. Patients completed a symptom diary card and measured their
peak expiratory flow rate (PEFR) daily. Exacerbations were defined as oral antibiotic treatment taken for a worsening of
respiratory symptoms. Symptoms and peak flow at exacerbation were analysed, and further measurements including
the COPD Assessment Test (CAT) and inflammatory markers were also compared to baseline values.
Results: At baseline, health status was significantly related to lung function, prognostic severity and systemic
inflammation. 51 exacerbations occurred in 22 patients. Exacerbation symptoms began a median (interquartile range)
of 4 (2, 7) days before treatment started and the median exacerbation duration was 16 (10, 29) days. 16% had not
recovered by 35 days. At exacerbation, mean PEFR dropped by 10.6% (95% confidence interval 6.9-14.2, p<0.001) and
mean CAT score increased by 6.3 units (3.6-9.1, p=0.001), median symptom count by 4 (2.25, 6, p<0.001), and mean
CRP by 9.0mg/L (2.3-15.8, p=0.011). Exacerbations where PEFR fell by ≥10% were longer with more symptoms at
onset.
Conclusion: Exacerbations of non-CF bronchiectasis are inflammatory events, with worsened symptoms, lung function
and health status, and a prolonged recovery period. Symptom diary cards, PEFR and CAT scores are responsive to
changes at exacerbation and may be useful tools for their detection and monitoring.
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Non-cystic fibrosis (CF) bronchiectasis is a chronic lung
disease characterised by irreversibly damaged and dilated
airways leading to recurrent episodes of bronchial sepsis
(‘exacerbations’) [1]. Estimates from the United States
suggest a prevalence of 52.3 cases per 100,000 [2], and
mortality appears to be increasing by 3% annually [3].
The economic burden is high [2], largely due to recur-
rent exacerbations.
There has been growing interest in non-CF bronchi-
ectasis, which has historically suffered from a lack of
high-quality research [4]. Exacerbations cause signifi-
cant morbidity and may also accelerate disease progres-
sion; recent clinical trials have therefore focused on
strategies to prevent them [5,6]. However, changes in lung
function and symptomatology during their development
and recovery - especially community-treated exacerba-
tions - have not been previously described. These data are
vital to develop improved disease monitoring tools or sur-
rogate trial endpoints.
To address this lack of data we have investigated
changes in lung function, symptoms, health status and
inflammation before, during and after community-
treated exacerbations in patients with non-CF bronchi-
ectasis. Some preliminary analysis has previously been
presented in abstract form [7].
Methods
Study design
This was a prospective, observational cohort study con-
ducted using outpatients at the Royal Free Hospital,
London, United Kingdom. Ethical approval was obtained
(reference 10/H0720/43) and all patients provided written,
informed consent.
Recruitment and stable visits
Patients with a clinical diagnosis of bronchiectasis were
identified from general respiratory outpatient clinics. At
screening, bronchiectasis was confirmed on previous im-
aging. Aetiology was determined according to British
Thoracic Society guidance [1] and recorded as idiopathic
if no cause was found after investigation. Spirometry was
performed in accordance with ATS/ERS guidance [8] using
a Vitalograph Gold Standard spirometer (Vitalograph Ltd.,
Maids Morton, UK). Blood was collected for analysis of in-
flammatory markers. Patients also completed the Chronic
Obstructive Pulmonary Disease (COPD) Assessment Test
( C A T )[ 9 ]a n dS tG e o r g e ’s Respiratory Questionnaire
(SGRQ) [10]. CT images were independently assessed
using the Bhalla score [11] by two independent observers
(JAH and JRH) and differences resolved by consensus.
Prognostic disease severity was calculated using the Bron-
chiectasis Severity Index (BSI) [12] online calculator (www.
bronchiectasisseverity.com).
Once enrolled, patients monitored their morning post-
medication peak expiratory flow rate (PEFR) each day,
recording the best of three attempts (using a Mini-
Wright peak flow meter, Clement Clarke International
Ltd, Harlow, UK). They also recorded the presence or
worsening (if the symptom was usually present) of up to
15 symptoms and any changes in their treatment on
daily diary cards. The diary card, available in the online
data supplement (Additional file 1), was designed to re-
flect the breadth of symptoms that may occur during
bronchiectasis exacerbations; all patients received careful
training at their first and subsequent appointments.
After recruitment, patients attended six-monthly when
stable and exacerbation-free for the preceding four
weeks. These and the recruitment visits provided base-
line data for comparison.
Exacerbation visits
Patients with worsening symptoms attended the research
clinic where they were assessed by a doctor specialised
in respiratory medicine (SEB/ARCP/RS/AJM/JRH) and
received treatment for exacerbation as needed. If an ex-
acerbation was confirmed clinically, further blood was
sampled, spirometry performed and the CAT adminis-
tered. Patients who were unable to attend the clinic, or
who did not notify the study team at the time of exacer-
bation, recorded their symptoms, PEFR, and the dates
and type of any antibiotic therapy taken on their daily
diary cards.
Sample analysis
Blood was analysed for C-reactive protein (CRP) using a
Modular Analytics E170 Module (Roche, Burgess Hill,
UK) with detection limit 1 mg/L, plasma fibrinogen
using the Clauss method (IL ACL Top Coagulation
Analyzer; Instrumentation Laboratories, Lexington,
MA), and white cell and neutrophil counts using an au-
tomated XE-2100 analyser (Sysmex Corp, Kobe, Japan).
Serum was stored at −80°C and batch analysed for inter-
leukin (IL)-6 using commercial sandwich ELISA kits
(RD Systems, Abingdon, UK).
Statistical analysis
The first two weeks of PEFR data following study enrol-
ment were discarded to allow for the development of a
monitoring routine. Following this, baseline stable PEFR
for each patient was calculated as the mean of the first
14 days of diary card completion without worsening of
any symptoms and subsequent PEFR values were con-
verted to % stable for all analyses and reporting. Baseline
day-to-day variability over the same period was calcu-
lated as % of recent best using the formula [(highest
PEFR – lowest PEFR)/highest PEFR]* 100 [13].
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taken for worsening chest symptoms, without hospital
admission, as reported by the patient or administered by
the study team. Day 0 (exacerbation onset) was defined
as the first day of antibiotic therapy; data from the pre-
ceding two weeks and subsequent five weeks were in-
cluded for analysis. Only exacerbations treated with
antibiotics were included and this was therefore a
healthcare utilisation definition of exacerbation.
To examine the length of treated exacerbations within
this period, symptomatic onset was defined as the first
of ≥2 consecutive days between day −14 and day 0
where ≥2 extra symptoms were recorded on the diary
cards with no further symptom-free days between that
day and day 0. Symptomatic recovery was defined as the
first of ≥2 symptom-free days, or (if there was continu-
ous symptom recording) when the number of symptoms
returned to the pre-exacerbation count.
Data were tested for Normality using the Kolmogorov-
Smirnov test and reported as median (interquartile range
[IQR]) or mean (standard deviation [SD]) as appropriate.
Means were compared using paired or independent t-
tests as appropriate and medians were compared using
the Wilcoxon signed-rank test for related samples or the
independent-samples median test as appropriate. Rela-
tionships between variables were assessed using Pear-
son's correlation coefficient. Missing data were not
imputed. SPSS Statistics version 21.0 (SPSS Inc) was
used for analysis and results were deemed statistically
significant at the 5% level (p values of <0.05).
Results
32 patients, enrolled between August 2010 and August
2012, were included for analysis. The median follow-up
duration was 491 days. 51 exacerbations occurred in 22
of these patients during the study period with a median
(IQR) of 1 (1, 3) per patient. Figure 1 illustrates the data
flow for this study.
Patient characteristics at baseline
Patient and disease characteristics at recruitment are re-
ported in Table 1. Most patients were female, with a mean
age of 61 years, with mainly post-infectious or idiopathic
disease, typical for a European secondary care cohort.
As expected, there were significant relationships be-
tween health status and the physiological, prognostic
and inflammatory severity of bronchiectasis. SGRQ
scores were significantly correlated with FEV1 % predicted
(r=−0.507, p=0.003), BSI scores (r=0.587, p<0.001),
and the serum inflammatory markers CRP [r=0.390,
p=0.03], fibrinogen [r=0.460, p=0.013], and log[IL-6]
[r=0.480, p=0.044]). CAT scores were closely related to
SGRQ scores (r=0.799, p<0.001) and also significantly
related to FEV1,( r = −0.624, p<0.001), BSI scores
(r=0.493, p=0.004) and inflammation (fibrinogen, r=
0.455, p=0.013). No differences in baseline characteristics
were detected between patients who suffered an exacerba-
tion during the study period and those who did not.
Mean day-to-day PEFR variability in these patients was
12.4% (8.2), and there was no significant difference in
Figure 1 Data flow for this study. *Missing baseline-exacerbation pairs were due to a lack of baseline visits between exacerbations for comparison;
further numbers variation is due to missing investigational data.
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Exacerbations
21 of the 22 patients who experienced exacerbations re-
corded PEFR and symptoms during 47 events, with data
available for 82% and 78% of days respectively. The
time-course of the changes in PEFR and symptoms
during exacerbation onset and recovery is illustrated in
Figure 2. All exacerbations received oral antibiotic ther-
apy with a minimum duration of seven days.
Changes in physiology with exacerbation
The mean PEFR first began to fall 6 days before treat-
ment onset (day −6), becoming statistically significant at
day −3 (4.9% reduction, 95% CI 1.6-8.2, p =0.005 for
Table 1 Characteristics at study enrolment of all 32 patients with non-CF bronchiectasis and of the subset of 22 who
experienced exacerbations during the study period
Whole cohort (n=32) Patients experiencing exacerbations
during study period (n= 22)
Age (years), mean (SD) 61 (12) 59 (12)
Female patients, n (%) 27 (84) 19 (86)
Duration of follow up (days), median (IQR) 491 (386,603) 506 (390,648)
Ever smokers, n (%) 10 (31) 6 (27)
Aetiology, n (%) Post-infectious: 16 (50) Post-infectious: 13 (59)
Idiopathic: 11 (34) Idiopathic: 5 (23)
Rheumatological: 2 (6) Rheumatological: 1 (4)
Other: 3 (9) Other: 3 (14)
Bhalla score, mean (SD) 12 (9) 12 (9)
Number of lobes involved, median (IQR) 3.5 (2,5) 3.5 (2,5)
BSI score, median (IQR) 8.5 (4,12.8) 9 (4.5,11.3)
Severity (BSI classification), n (%) Mild: 9 (28) Mild: 6 (27)
Moderate: 8 (22) Moderate: 4 (18)
Severe: 15 (50) Severe: 12 (55)
Self-reported exacerbation frequency in previous year, median (IQR) 3 (2,5.8) 3 (2.3,6)
Asthma diagnosis, n (%) 7 (22) 6 (27)
Previous pseudomonas on sputum culture, n (%) 7 (22) 5 (23)
Previous hospitalisation, n (%) 9 (28) 8 (36)
Treatment details (all given as n (%))
Short-acting inhaled bronchodilator 13 (41) 10 (45)
Long-acting inhaled bronchodilator 12 (38) 8 (36)
Inhaled corticosteroid use 16 (50) 11 (50)
Long term macrolide therapy, n (%) 2 (6) 2 (9)
Lung function measurements: (all given as mean (SD))
FEV1(L), mean (SD) 1.96 (0.90) 2.02 (0.95)
FEV1% predicted (SD) 78 (26) 76 (28)
FEV1/FVC ratio, (SD) 0.71 (0.15) 0.71 (0.17)
Stable PEFR (L/min), (SD) 334 (104) 337 (110)
PEFR variability, % best (see text) 12.4 (8.2) 13.8 (9.4)
SGRQ and CAT scores (all given as mean (SD))
Symptoms 48.8 (24.3) 50.2 (26.1)
Activity 40.3 (27.8) 41.8 (27.7)
Impact 27.2 (16.5) 29.4 (14.9)
Total SGRQ score 34.8 (18.1) 37.6 (16.9)
CAT score 16.6 (7.0) 17.2 (7.1)
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on day 0, with a 10.6% reduction from stable (95% CI 6.9-
14.2, p<0.001), corresponding to a mean absolute reduc-
tion of 31 (19–42) L/min (p< 0.001). The mean PEFR
returned to pre-exacerbation values at day 25, although by
day 11 the difference was no longer statistically significant.
Importantly, there was no significant difference in mean
PEFR at day 0 in patients with a comorbid asthma diagno-
sis (11 exacerbations) compared to those without (93.4%
(7.1) vs 88.5 (8.9), p=0.112), and the PEFR reduction at ex-
acerbation was not related to baseline PEFR variability. In
community treated exacerbations there is therefore a statis-
tically significant reduction in PEFR from at least three days
before until at least eleven days following treatment onset.
In those exacerbations that were sampled and where
baseline-exacerbation pairs were available (n= 28, in 20
patients), there was also a moderate reduction in FEV1
at exacerbation compared to previous baseline, both in
absolute (90ml, 95% CI 15–164, p=0.019) and % stable
(4.1%, 95% CI 0.6-7.5, p= 0.022) values.
Changes in symptoms with exacerbation
The number of reported daily symptoms increased from
a median (IQR) of 0 (0, 1) at day −14 to 4 (2.25, 6 [p<
0.001]) at treatment onset. The most prevalent symp-
toms reported at exacerbation were increased cough
(61%), breathlessness (59%) and change in sputum
colour (55%). Figure 3 illustrates the prevalence of each
of the 15 recorded symptoms at exacerbation onset.
Using the definition detailed above, symptomatic
exacerbation onset and recovery could be defined in 37
exacerbations, with the remainder not recording a symp-
tomatic increase. The median (IQR) onset was 4 (7,2)
days before treatment, and median overall exacerbation
length 16 (10,29) days. There was a significant correl-
ation between exacerbation length and the number of
symptoms at treatment onset (r= 0.458, p=0.004). Al-
though the median recovery time after treatment start
was 9 (5,20.5) days, 6 exacerbations (16%) had still not
recovered symptomatically at 35 days after treatment
onset. Figure 4 illustrates the proportion of these
Figure 2 Mean PEFR (A) and median diary card symptom count (B) before, during and after treated exacerbations of non-CF bronchiectasis.
Day 0 (highlighted) was the first day of antibiotic treatment. The bars represent 95% confidence intervals (A) and interquartile ranges (B).
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Figure 4 Proportion of 37 exacerbations meeting symptomatic criteria for exacerbation by day. Day 0 was the first day of treatment
(highlighted). 16% of exacerbations had not recovered by day 35 based on failure to return to baseline on diary card symptom recording.
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each day of the time-course.
Changes in health status with exacerbation
Paired CAT scores were available at exacerbation and
preceding baseline from 23 exacerbations in 17 patients.
At exacerbation, there was a mean (SD) increase of 6.3
(6.3) units over baseline (95% CI 3.6-9.1, p<0.001).
Relationship between changes in PEFR, symptoms and
health status
Greater falls in PEFR at exacerbation onset were associ-
ated with greater symptom burden and prolonged recov-
ery. In 14 exacerbations where PEFR fell by ≥10%,
compared to 17 in which it did not, there was a higher
median (IQR) day 0 symptom count (3 [1.5, 4.5] vs 5.5
[5,8], p=0.009), and longer median (IQR) symptomatic-
ally defined exacerbation period (10 days [8,14] vs 17
[13, 28], p=0.047).
There was also a significant correlation between the
change in CAT score at exacerbation and the number of
symptoms at exacerbation onset (r= 0.455, p =0.038).
Changes in systemic inflammatory markers with
exacerbation
Table 2 reports the systemic biomarker results where
paired samples were available at exacerbation onset and
preceding baseline review. Serum fibrinogen, CRP and IL-
6 all increased significantly at exacerbation. Interestingly
the delay between symptom onset and treatment was
weakly correlated to inflammatory change at exacerbation
(rise in CRP; r = 0.469, p = 0.049) implying that delayed
presentation associates with greater inflammation.
Discussion
This is the first study to conduct a detailed, prospective
assessment of changes in symptoms and physiology prior
to, at onset, and through the recovery of exacerbations
in patients with non-CF bronchiectasis.
The key messages may be summarised thus. First, lung
function and symptoms deteriorate between three and
four days prior to patients initiating therapy, suggesting
a window for earlier detection and treatment of exacer-
bations. A larger fall in PEFR was associated with greater
symptom burden at exacerbation onset and a longer
symptom recovery time. Second, the overall burden of
these community exacerbations is high: the median symp-
tom duration was 16 days, with lung function statistically
abnormal for two weeks. Third, these community treated
exacerbations were associated with a measurable systemic
inflammatory response. Finally, the CAT reflects health
status in the stable state and is responsive to changes at
exacerbation in patients with bronchiectasis.
PEFR is a simple and well-established tool for assessing
day-to-day changes in lung function. Patients learn the
technique easily, the device is cheap and daily measure-
ments are not unduly burdensome. Although spirometry
is the most widely used measure of lung function in bron-
chiectasis, it requires more training and equipment and is
not sufficiently responsive to changes with treatment [13];
newer techniques include the Lung Clearance Index (LCI)
[14], although this requires still more specialist equipment
and has yet to be evaluated in monitoring treatment re-
sponse. In principle, PEFR therefore remains an attractive
technique for disease self-monitoring.
We have shown a reduction of >10%, or 30L/min, in
PEFR during these community-treated exacerbations.
Full recovery did not occur until 25 days after treatment
initiation. We have also shown that the reduction in
PEFR at exacerbation is larger, and more closely related
to reported symptoms and exacerbation duration, than
FEV1. In addition, where there was a large change in
PEFR, patients experienced worse health status, more
symptoms and longer exacerbations. These data suggest
that, where large changes are present, PEFR may be an
effective surrogate marker for important clinical out-
comes. However, changes below the level of day-to-day
variability will be difficult to detect in individuals, par-
ticularly asthmatics, and this limits the utility of PEFR in
making treatment decisions. Nonetheless, we have
shown that PEFR change is measurable across a popula-
tion and this, combined with its simplicity, may still
prove more useful than spirometry for studies looking to
assess changes in lung function.
This study is the first to describe the symptomatic de-
velopment and duration of treated exacerbations of non-
CF bronchiectasis. At the time of planning this study,
there were no widely accepted symptomatic criteria for
Table 2 Serum inflammatory markers at baseline and exacerbation in non-CF bronchiectasis
Baseline
(Mean, SD)
Exacerbation
(Mean, SD)
Number of exacerbations
(Number of patients occurred in)
P-value for comparison
White cell count (x10
9/L) 6.8 (2.5) 7.3 (2.5) 25 (18) 0.351
Neutrophil count (x10
9/L) 4.2 (1.9) 4.5 (1.7) 23 (18) 0.538
Fibrinogen (g/L) 3.6 (0.5) 4.1 (0.9) 20 (16) 0.001
CRP (mg/L) 3.0 (2.0) 12.0 (16.7) 24 (18) 0.011
IL-6 (log10 pg/mL) 0.65 (0.48) 0.97 (0.51) 22 (15) 0.038
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quently been published [1]. In order to reflect current
clinical practice for these mild community-treated exac-
erbations the decision to treat with antibiotics was there-
fore based either on the clinical judgement of the
treating clinician or on the patient taking their stand-by
antibiotic courses without formal criteria. However, in
order to examine the length of treated exacerbations, a
symptomatic definition was needed. Criteria defined
elsewhere [1] require all of systemic upset, increased
sputum volume or viscosity and increased sputum puru-
lence to be present prior to antibiotic therapy being pre-
scribed. Applying these criteria to our dataset, a day of
onset could only be accurately defined in 17/47 (36%) of
exacerbations. This was partially because the diary cards
did not include ‘viscosity’ as a specific symptom, and be-
cause individual clinical judgement was used by both pa-
tients and clinicians when taking the decision to start
antibiotics. Our simpler criteria, using two or more
symptoms recorded on the diary cards over two or more
days, were useful for detecting the symptomatic exacer-
bation onset and recovery of treated exacerbations, al-
though we have not examined the utility of this
definition in making treatment decisions. Surprisingly,
increased cough was only recorded as a symptom in
60% of exacerbations, despite its prevalence having been
reported as high as 98% at diagnosis [15]. The reason
behind this is unclear, but may be a combination of re-
duced perception of a chronic symptom, under-
reporting on the diary cards, or heterogeneity in the
(non-standardised) indications for antibiotic therapy.
Patients waited on average four days after symptoms
increased before they started therapy, and we found a
weak but significant relationship between treatment
delay and inflammatory change at exacerbation. This is
potentially important, as it suggests that starting treat-
ment early might reduce the severity and duration of the
exacerbation. However, in some cases this delay may be
appropriate, for example if the initial presentation is
with viral upper respiratory tract symptoms for which
antibiotic treatment would not necessarily be appropri-
ate. The reasons underlying delays in treatment, and the
clinical impact on exacerbation progression and recov-
ery, therefore warrant further investigation.
In non-CF bronchiectasis, the SGRQ is currently the
best validated measure of respiratory health status [10].
The CAT is an eight-item questionnaire, widely used as
a simple and reliable measure of the impact of symp-
toms on health status [9] and the severity of exacerba-
tions [16] in COPD, and is quick and simple to
complete. We have shown here that the CAT is closely
related to SGRQ score at baseline, with the strength of
this relationship (r= 0.799) almost identical to that re-
ported in COPD [9] and slightly stronger than previously
reported in bronchiectasis [17], and also related to other
important markers of lung function, disease severity and
inflammation. Importantly, it was also sensitive to
changes at exacerbations of bronchiectasis and corre-
lated to exacerbation symptoms. The increase from
baseline at bronchiectasis exacerbation was much higher
than the reported minimum clinically important differ-
ence for COPD of 2 points [18]. The CAT may therefore
be a simple method to monitor health status at baseline
and exacerbation in bronchiectasis, and may be useful as
a research tool for these patients.
Exacerbations of bronchiectasis are inflammatory
events and heightened systemic inflammation has previ-
ously been shown, albeit in hospitalised patients com-
pared to a separate group of patients who were not
exacerbating [19]. For the first time, we have demon-
strated increased systemic inflammation in the same pa-
tients between exacerbation and stable state in milder
outpatient events. The largest rise at exacerbation, in
CRP, crossed the usual upper limit of normal (5mg/dL)
and related to symptoms at onset. CRP will be available
to most researchers and may provide a useful marker to
monitor inflammation during these events.
Strengths of this study
This study provides accurate longitudinal information,
prospectively collected, to track the development and re-
covery of exacerbation. This is in contrast to previous
studies, which have been retrospective or compared ex-
acerbation and stable state across different patients. In
addition, the patients studied here were not hospitalised;
their disease is mainly post-infectious or idiopathic, and
therefore likely to be representative of the wider popula-
tion of patients with bronchiectasis. The use of these
simple clinical measurements in this population should
be widely applicable to other researchers and clinicians
in the field.
Limitations of this study
Our data were observational and dependent on patients’
self-recording of measurements and exacerbation dates,
as well as attending clinic for review when unwell. It is
therefore possible that we did not detect all exacerba-
tions that occurred within the study population, as well
as being limited by other factors affecting observational
research such as the non-standardisation of exacerbation
treatment and missing data. As noted above, our defin-
ition of exacerbation was broad and based on the judge-
ment of the patient or treating clinician. As such, some
of these events may have not have met formal a priori
criteria for exacerbation diagnosis had these been de-
fined. In addition, our sample size was not large, particu-
larly when looking at paired samples, and although it
appears to represent a usual outpatient secondary care
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these factors may have limited our ability to detect more
subtle changes at exacerbation, they do not diminish the
positive associations that we have reported.
Conclusions
For the first time in non-CF bronchiectasis, we have de-
scribed in detail the symptomatic and lung function
changes during the development and recovery from ex-
acerbation, and the relationships between lung function,
exacerbation length, systemic inflammation and health
status during exacerbations. We have shown that PEFR
and symptom diary cards provide simple measures to de-
fine, track and monitor exacerbations, and that the CAT
questionnaire may be a useful tool to monitor health
status.
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